Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
EVGN vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–0 Matrix Metrics)
SRZN Overall Winner
6-Pillar Tally: EVGN 1 – 4 SRZN (1 Tie)
Matrix Metrics: EVGN 0 – 7 SRZN
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas SRZN carries 46.6/100 (HOLD) at $29.98 (N/M Forward P/E, -485.4% operating margin).
- Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EVGN vs SRZN
EVGN
Evogene Ltd.
$0.34
-13.17% 1D
Market Cap
$6.0M
TTM Revenue
$1.7M
Forward P/E
N/M
Beta / 30D Vol
1.37β · 138% Vol
Unified Composite Score
44.1
HOLD
Tech 42.0
Fund 44.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
SRZN
Head-to-Head Winner
Surrozen, Inc. Common
$29.98
-7.24% 1D
Market Cap
$616.1M
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.29β · 67% Vol
Unified Composite Score
46.6
HOLD
Tech 40.0
Fund 33.0
Flow 65.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (EVGN 1 – 4 SRZN)
1. Valuation Multiples
SRZN
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
49.5x
2. Growth & Scale
SRZN
Revenue Growth (YoY)
-60.7%
+408.6%
Earnings Growth (YoY)
+0.0%
-37.0%
TTM Revenue (USD)
$1.7M
$11M
Market Cap
$6.0M
$616.1M
3. Profitability & Quality
SRZN
Gross Margin
-67.6%
N/A
Operating Margin
-858.2%
-485.4%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-182.8%
-62.8%
4. Balance Sheet & Cash Flow
EVGN
Cash Generation (TTM)
-$11M
-$31M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$6.5M Net Cash
$95M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SRZN
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
72.0% (5th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EVGN (0) vs SRZN (7)| Institutional Metric | EVGN | SRZN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.0M | $616.1M | SRZN | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -60.7% | +408.6% | SRZN | |
| Operating Margin (TTM) | -858.2% | -485.4% | SRZN | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -182.8% | -62.8% | SRZN | |
| 52-Week Range Position | 9% ($0–$1) | 69% ($12–$38) | SRZN | |
| Beta / 30D Volatility | 1.37β · 138% Vol | 1.29β · 67% Vol | SRZN | |
| Unified Institutional Score | 44.1 / 100 (HOLD) | 46.6 / 100 (HOLD) | SRZN | |
| Trailing 12M Revenue (USD) | $1.7M | $11M | Scale | |
| Gross Profit Margin (TTM) | -67.6% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 49.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$11M ($6.5M Net Cash) | -$31M ($95M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SRZN +33.34 pp
3M Horizon
SRZN +68.26 pp
6M Horizon
SRZN +71.54 pp
1Y Horizon
SRZN +202.86 pp
Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | EVGN Revenue | SRZN Revenue | EVGN Op. Margin | SRZN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| Q3 '25 | $0M | $0M | -873.1% | -1107.3% | EVGN |
| Q4 '25 | $0M | $0M | -1659.9% | -2393.8% | EVGN |
| Q1 '26 | $0M | $20M | -943.1% | -209.1% | SRZN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EVGN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SRZN
CONSOLIDATION
Current IV
72.0%
IV Percentile
5th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EVGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SRZN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ EVGN vs SRZN Key Questions & Quantitative Answers
As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas SRZN carries 46.6/100 (HOLD) at $29.98 (N/M Forward P/E, -485.4% operating margin). Technical & Structure Timing Caution: EVGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5); meanwhile SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRZN leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 3-period historical trajectory (Q3 '25 to Q1 '26), EVGN cumulative revenue shifted N/A while SRZN shifted N/A. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
SRZN screens cheaper on headline valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SRZN vs EVGN · Reverse Pair
EVGN vs KMDA
· Sector Peer
SRZN vs FTH
· Sector Peer
SRZN vs JSPR
· Sector Peer
SRZN vs TIL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma